Literature DB >> 20884440

Vascular response to a third generation everolimus-eluting stent.

Gregory J Wilson1, Barbara A Huibregtse, Elizabeth A Stejskal, Jody Crary, Ruth M Starzyk, Keith D Dawkins, James J Barry.   

Abstract

AIMS: In a non-injured porcine coronary artery model, the aim was to evaluate vascular compatibility of the novel platinum chromium everolimus-eluting PROMUS Element stent as compared to the following control stents: everolimus-eluting PROMUS (XIENCE V), bare metal Element, and polymer-only Element. METHODS AND
RESULTS: Stent pairs (n=228) evenly distributed among the four stent types were implanted in overlap configuration in 79 pigs at a targeted stent-to-artery ratio of 1.1:1. Similar numbers were explanted at each of 7, 30, 90, 180, and 270 days for pathological analysis. No stent-related mortality or morbidity was observed. There were no stent occlusions or strut fractures. The PROMUS Element was more radiopaque than PROMUS (relative densities 9.9 and 9.1, respectively) and demonstrated at all time points vascular compatibility similar to that of the control stents for endothelial cell coverage, inflammatory response, and neointima formation. At 30 days, parastrut fibrin was mild but greater (P<0.0001) for the drug-eluting stents than either for the bare metal or the polymer-only Element; however, by 90 days the fibrin had dissipated.
CONCLUSIONS: In the non-injured porcine coronary artery model, the PROMUS Element demonstrated vascular compatibility equivalent to PROMUS and the bare metal and polymer-only stents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884440     DOI: 10.4244/EIJ30V6I4A85

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.

Authors:  Wenda C Carlyle; James B McClain; Abraham R Tzafriri; Lynn Bailey; Brett G Zani; Peter M Markham; James R L Stanley; Elazer R Edelman
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

2.  Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.

Authors:  Alexander Sheehy; Steven Hsu; Amelie Bouchard; Pablo Lema; Claudine Savard; Louis-Georges Guy; Julie Tai; Igor Polyakov
Journal:  Cardiovasc Diabetol       Date:  2012-06-21       Impact factor: 9.951

3.  Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.

Authors:  Stefan Müller-Hülsbeck; Koen Keirse; Thomas Zeller; Herman Schroë; Juan Diaz-Cartelle
Journal:  J Endovasc Ther       Date:  2016-05-18       Impact factor: 3.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.